Abstract 5779: The discovery of the potent and selective PI3K/mTOR dual inhibitor PF-04691502 through structure-based drug design

Henry S. Cheng(Brigham and Women's Hospital), Peter C. Zhu(Pfizer (United States)), Qiyue Hu, Catherine Johnson(Pfizer (United States)), Caroline Rodgers, Sacha Ninkovic(Pfizer (United States)), Hai Wang(Chinese Academy of Agricultural Engineering), Shubha Bagrodia(Scripps Research Institute), Robert S. Kania(RG Biopharma (United States)), Khanh Tran(Pfizer (United States)), Phuong Thanh Le(Emory University), Andrew Pannifer(Pfizer (United Kingdom)), Michael Plewe(Pfizer (United States)), Lisa Guo(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Mitch Nambu(Pfizer (United States)), Dawn Nowlin(Pfizer (United States)), Simon Bailey(The University of Melbourne), Dilip Bhumalkar(Pfizer (United States)), Ted O. Johnson(Pfizer (United States)), Klaus Dress(Pfizer (United States)), Mason Pairish(Pfizer (United States)), Haitao Li(Hebei Medical University), Zhengyu Liu(The Ohio State University Wexner Medical Center), Kevin Liu(Pfizer (United States)), Xiao‐Jun Huang(Pfizer (United States)), Graham Smith(Queensland University of Technology), Michael R. Gehring(Pfizer (United States)), Daniel R. Knighton(Pfizer (United States)), Jacqui Hoffman(Pfizer (United States)), Samuel Li(Pfizer (United States)), Shaoxian Sun, Matthew A. Marx(Mirati Therapeutics (United States))
Cancer Research
April 1, 2010
10.1158/1538-7445.am10-5779
Cited by 0

Related Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
|Journal of Medicinal Chemistry|2014|587
MicroRNA‐146 represses endothelial activation by inhibiting pro‐inflammatory pathways
|EMBO Molecular Medicine|2013|427
Using the Golden Triangle to optimize clearance and oral absorption
|Bioorganic & Medicinal Chemistry Letters|2009|382